ClearPoint Neuro Completes 4,000th ClearPoint® Neuro Navigation Procedure
November 30 2020 - 9:15AM
ClearPoint Neuro, Inc. (Nasdaq: CLPT), a leader in image-guided
stereotactic neurosurgery, announced that its 4,000th neurosurgical
procedure using the ClearPoint Neuro Navigation System was
completed earlier this month at Dartmouth-Hitchcock Medical Center
in Lebanon, New Hampshire.
The ClearPoint Neuro Navigation System is
currently utilized at 60 of the top neurosurgical centers in the
United States. The System empowers MRI-guidance for a range of
procedures including deep brain stimulation (“DBS”), laser
catheters, drug delivery and biopsies allowing neurosurgeons to
leverage live MRI imaging to decide, guide and confirm procedures
with sub-millimetric accuracy.
“We are happy to be partners with ClearPoint on their 4,000th
case,” stated Dr. Joshua Aronson, Assistant Professor of Surgery,
Geisel School of Medicine, Dartmouth. “This milestone is a
testament to ClearPoint’s MRI-guided technology, enabling accurate
and safe stereotactic neurosurgery procedures such as DBS placement
where patients are placed under general anesthesia at the onset,
and awaken when the procedure is complete. The Dartmouth-Hitchcock
Parkinson’s Disease and Movement Disorders Program is pleased to
offer ClearPoint MRI-guided DBS placement to patients with
Parkinson’s Disease and Essential Tremor.”
“This milestone is a testament to the work of
our entire team of clinical specialists, as well as our operations
and manufacturing teams,” commented Jacqueline Keller, Vice
President, Marketing for ClearPoint Neuro. “We are proud that our
technology has helped neurosurgeons accurately treat so many
patients at 60 of the top neurosurgical centers in the United
States. We look forward to supporting another 4,000-plus
procedures, both in the United States and overseas, in the coming
years.”
About ClearPoint
Neuro
ClearPoint Neuro’s mission is to improve and
restore quality of life to patients and their families by enabling
therapies for the most complex neurological disorders with pinpoint
accuracy. Applications of the Company’s current product portfolio
include deep-brain stimulation, laser ablation, biopsy,
neuro-aspiration, and delivery of drugs, biologics and gene therapy
to the brain. The ClearPoint Neuro Navigation System has FDA
clearance, is CE-marked, and is installed in 60 active clinical
sites in the United States. The Company’s SmartFlow® cannula is
being used in partnership or evaluation with 25 individual
biologics and drug delivery companies in various stages from
preclinical research to late stage regulatory trials. To date, more
than 4,000 cases have been performed and supported by the Company’s
field-based clinical specialist team which offers support and
services for our partners. For more information, please visit
www.clearpointneuro.com.
Forward-Looking Statements
Statements herein concerning the Company’s
plans, growth and strategies may include forward-looking statements
within the context of the federal securities laws. Statements
regarding the Company's future events, developments and future
performance, as well as management's expectations, beliefs, plans,
estimates or projections relating to the future, are
forward-looking statements within the meaning of these laws.
Uncertainties and risks may cause the Company's actual results to
differ materially from those expressed in or implied by
forward-looking statements. Particular uncertainties and risks
include those relating to: the impact of COVID-19 and the measures
adopted to contain its spread; future revenues from sales of the
Company’s ClearPoint Neuro Navigation System products; the
Company’s ability to market, commercialize and achieve broader
market acceptance for the Company’s ClearPoint Neuro Navigation
System products; and estimates regarding the sufficiency of the
Company’s cash resources. More detailed information on these and
additional factors that could affect the Company’s actual results
are described in the “Risk Factors” section of the Company’s Annual
Report on Form 10-K for the year ended December 31, 2019, and the
Company’s Quarterly Report on Form 10-Q for the three months ended
September 30, 2020, both of which have been filed with the
Securities and Exchange Commission.Contact:
Harold A. Hurwitz, Chief Financial Officer(949)
900-6833info@clearpointneuro.com
Jacqueline Keller, Vice President, Marketing(949)
900-6833info@clearpointneuro.com
ClearPoint Neuro (NASDAQ:CLPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
ClearPoint Neuro (NASDAQ:CLPT)
Historical Stock Chart
From Sep 2023 to Sep 2024